A director at Bangkok Dusit Medical Services Public Company Limited bought 1,066,400 shares at 18.300THB and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
ASEAN Gems Corporate Highlights | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt18.70/Target: Bt32.00) BDMS attended the ASEAN Gems Conference and was positively received by the investors. Investors mainly appreciate BDMS for its strong defensive quality and attractive valuation. The company’s long-term growth plan remains strong with its focus shifting more towards increasing bed occupancy instead of expanding branches. Middle East risks are limited given low exposure. BDMS also focuses on gain...
Top Stories ASEAN Gems Corporate Highlights | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt18.70/Target: Bt32.00) BDMS attended the ASEAN Gems Conference and was positively received by the investors. Investors mainly appreciate BDMS for its strong defensive quality and attractive valuation. The company’s long-term growth plan remains strong with its focus shifting more towards increasing bed occupancy instead of expanding branches. Middle East risks are limited given low exposure. BDMS also f...
Greater China Economics | Money Supply Feb 26 money and credit data came in above expectations, helped by the Chinese New Year effect and better new bank credit and TSF at Rmb0.90t and Rmb2.38t respectively. This lifted M2 growth to 9.0% yoy, while M1 growth came in at 5.9% yoy. While the 2M26 data was above market expectations, the credit cycle is not in an upswing, as total credit growth edged lower to 6.0% yoy, and TSF growth stayed flat at 8.2% yoy. Sector Update | Healthcare The HSH...
Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.70/Target: Bt32.00) BDMS delivered a neutral tone with 2026 revenue growth guidance of 2-4% yoy, driven mainly by foreign patients. Cost control and margin stability (24% EBITDA) remain priorities amid weak Thai demand. Middle East tensions pose limited risk given BDMS’ low exposure, though 1Q26 outlook is soft due to Cambodia-related pressure. Copayment insurance impact will emerge gradually over two years. Despite headwinds, BDM...
Top Stories Company Update | BANPU (Pre-amalgamation) (BANPU TB/HOLD/Bt5.75/Target: Bt5.50) The gas business outlook remains positive, supported by growing demand in the US. We expect Henry Hub prices to trend higher over the next two years. Meanwhile, the coal market is relatively flat yoy. Although demand remains weak, supply is constrained by ongoing uncertainty surrounding production quotas and export policies in Indonesia. The NewCo restructuring process is progressing as planned and is e...
Greater China Economics | PMI February PMI was below Bloomberg's consensus, with manufacturing PMI edging down to 49.0 (-0.2pt mom) and non-manufacturing PMI staying contractionary at 49.5 (+0.1pt mom), partly reflecting Chinese New Year seasonality. New export orders sub-index fell to 45.0 (-2.8pt mom) for manufacturing PMI and 44.7 (-2.2pt mom) for services PMI. The manufacturing business expectations sub-index improved to 53.2 (+0.6pt mom) ahead of the Two Sessions. Company Results | AS...
Greater China Strategy | Alpha Picks: March Conviction Calls Chinese equities consolidated further in February, with the HSI and MSCI China Index declining 2.8% mom and 5.6% mom, respectively. March is expected to be volatile, as there are signs that the Middle East conflict could last for a while. We focus on names which have greater domestic exposure, adding Anta, China Duty Free, FII, Futu, Kuaishou and Tencent to our BUY list. Indonesia Strategy | Alpha Picks: Rotating To Commodities Amid M...
Greater China Economics | China Investors expect the NPC to set a 2026 real GDP growth target of 4.5-5.0% yoy, with policy support led primarily by fiscal measures while monetary easing remains complementary. The official deficit is likely capped at 4%, though augmented fiscal expansion via special bond issuance will provide additional support. The 15th Five-Year Plan is expected to prioritise hard-tech self-reliance, advanced manufacturing and curbing industrial involution, with only target...
Company Results | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt21.40/Target: Bt32.00) 4Q25 net profit was Bt3.7b (-14.8% yoy), in line with estimates, dragged by flood-related costs and provisions. Revenue grew modestly, supported by Thai and non-Cambodian foreign patients, though Cambodian revenue dropped sharply. Margins weakened on higher costs and tax rate. Tensions with Cambodia remain a drag. BDMS announced a total 2025 dividend of Bt1.00/share (~4.7% yield). Copayment impact will be grad...
Top Stories Company Update | AP (Thailand) (AP TB/BUY/Bt9.40/Target: Bt10.80) 4Q25 earnings were in line with expectations, flat yoy and up 12% qoq, marking the quarterly peak for the year. AP plans to launch projects worth Bt55b in 2026, the highest value among peers. It targets single-digit growth in presales and transfers in 2026. Fundamentals and dividend payment are expected to support its share price. Maintain BUY. Target price: Bt10.80. Company Update | Bangkok Bank (BBL TB/HOLD/Bt176...
Greater China Strategy | Alpha Picks: February Conviction Calls Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite the risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, and Meituan to our SELL list. Indonesia Strategy | Alpha Picks: From MSCI Shock To Policy-Driven Rebala...
Greater China Sector Update | China Property CRIC data show that the top 100 developers’ contracted sales fell 24.7% yoy in Jan 26, while new-home sales in 28 major cities declined 36% yoy. Second-hand transactions in three Tier 1 cities rose 1% yoy. Maintain UNDERWEIGHT but deepening industry downturn leads to rising possibility of policy support, supporting selective exposure. CR Land remains our top pick, with P/B at 1SD below the five-year mean, and PE and yield near the five-year average....
Greater China Company Update | NAURA Technology Group (002371 CH/BUY/Rmb497.68/Target: Rmb571.70) We see multiple upside risks to our assumption about NAURA for 2026-27. Domestic foundries and memory IDMs are likely to further raise their capex plans for advanced nodes given robust downstream demand and capacity shortage, while the mature node capex may end up better than feared thanks to overflow demand from global Tier 1 foundries. On the other hand, localisation efforts are accelerating signi...
Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.00/Target: Bt32.00) BDMS is expected to report a substantial earnings contraction in 4Q25, with net profit forecast at Bt3.81b (-12.1% yoy, -11.8% qoq), pressured by flood-related costs, higher provisions, and rising expenses, despite moderate revenue growth on a strong epidemic-driven Thai patient base. Margins are projected to fall materially. While near-term earnings face headwinds, the epidemic remains a key support, copayment...
Top Stories Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.00/Target: Bt32.00) BDMS is expected to report a substantial earnings contraction in 4Q25, with net profit forecast at Bt3.81b (-12.1% yoy, -11.8% qoq), pressured by flood-related costs, higher provisions, and rising expenses, despite moderate revenue growth on a strong epidemic-driven Thai patient base. Margins are projected to fall materially. While near-term earnings face headwinds, the epidemic remains a key supp...
Greater China Strategy | Alpha Picks: January Conviction Calls Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December pic...
Greater China Strategy | Alpha Picks: January Conviction Calls Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December...
Greater China Sector Update | China Property Demand stayed weak in Nov 25, with new-home sales in 28 cities down 42% yoy and second hand home prices in most cities falling. Land auctions in Shanghai and Hangzhou cooled, with most plots near reserve prices. We maintain UNDERWEIGHT on China property, with CR Land as our top pick for its consistent earnings outperformance. Sector Update | Macau Gaming Macau’s Nov 25 GGR reached MOP 21.1b, down 12% mom but up 14% yoy, and recovering to 92% o...
Greater China Economics | Money Supply M1 growth fell to 6.2% yoy in October, short of expectations, while M2 growth eased to 8.2% yoy. New bank loans dropped sharply to Rmb0.22t, and new TSF fell to Rmb0.81t, both below forecasts. Outstanding TSF and bank loan growth moderated to 8.5% (-0.2ppt mom) and 6.5% yoy (-0.1ppt mom) respectively, with the decline led by household loans. The numbers are not encouraging. Sector Update | Automobile China’s PV retail sales basically remained flat yoy in O...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.